Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

Hypoxia unleashes the invasive and metastatic potential of tumor cells by largely unknown mechanisms. The Met tyrosine kinase, a high affinity receptor for hepatocyte growth factor (HGF), plays a crucial role in controlling invasive growth and is often overexpressed in cancer. Here we show that: (1) hypoxia activates transcription of the met protooncogene, resulting in higher levels of Met; (2) hypoxic areas of tumors overexpress Met; (3) hypoxia amplifies HGF signaling; (4) hypoxia synergizes with HGF in inducing invasion; (5) the proinvasive effects of hypoxia are mimicked by Met overexpression; and (6) inhibition of Met expression prevents hypoxia-induced invasive growth. These data show that hypoxia promotes tumor invasion by sensitizing cells to HGF stimulation, providing a molecular basis to explain Met overexpression in cancer.

[1]  P. Comoglio,et al.  Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. , 1998, Journal of cell science.

[2]  T. Nakamura,et al.  Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Blagosklonny Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). , 2001, International journal of oncology.

[4]  W. Birchmeier,et al.  Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. , 1992, The EMBO journal.

[5]  K. Matsumoto,et al.  Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. , 1993, The Journal of biological chemistry.

[6]  D. Gomez,et al.  Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. , 1999, European journal of biochemistry.

[7]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[8]  M. Tsao,et al.  Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. , 1992, Oncogene.

[9]  W. Risau,et al.  Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. , 1997, The Biochemical journal.

[10]  G. V. Vande Woude,et al.  Met-HGF/SF: tumorigenesis, invasion and metastasis. , 2007, Ciba Foundation symposium.

[11]  J. Bruix,et al.  c‐met mRNA overexpression in human hepatocellular carcinoma , 1994, Hepatology.

[12]  D. Mottet,et al.  HIF‐1 and AP‐1 Cooperate to Increase Gene Expression in Hypoxia: Role of MAP Kinases , 2001, IUBMB life.

[13]  T. Sanchez-Elsner,et al.  Endoglin Expression Is Regulated by Transcriptional Cooperation between the Hypoxia and Transforming Growth Factor-β Pathways* , 2002, The Journal of Biological Chemistry.

[14]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[15]  M. Norris,et al.  Hypoxia-induced Protein Binding to O2-responsive Sequences on the Tyrosine Hydroxylase Gene (*) , 1995, The Journal of Biological Chemistry.

[16]  P. Comoglio,et al.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas , 2000, Oncogene.

[17]  L. Naldini,et al.  The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation , 1991, Molecular and cellular biology.

[18]  R. Hill,et al.  Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Rofstad,et al.  Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. , 2002, Cancer research.

[20]  J. Rubin,et al.  Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. , 1993, Biochimica et biophysica acta.

[21]  P. Comoglio,et al.  EXPRESSION OF Met PROTEIN IN THYROID TUMOURS , 1996, The Journal of pathology.

[22]  R. Klausner,et al.  The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.

[23]  W. Birchmeier,et al.  Hepatocyte growth factor/scatter factor induces a variety of tissue- specific morphogenic programs in epithelial cells , 1995, The Journal of cell biology.

[24]  M. Noble,et al.  Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros , 1995, The Journal of cell biology.

[25]  D. Seol,et al.  Transcriptional activation of the Hepatocyte Growth Factor receptor (c-met) gene by its ligand (Hepatocyte Growth Factor) is mediated through AP-1 , 2000, Oncogene.

[26]  A. Bardelli,et al.  Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists , 1999, Oncogene.

[27]  E. Gherardi,et al.  Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Semenza,et al.  HIF-1, O2, and the 3 PHDs How Animal Cells Signal Hypoxia to the Nucleus , 2001, Cell.

[29]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[30]  M. Sharpe,et al.  Scatter factor/hepatocyte growth factor is essential for liver development , 1995, Nature.

[31]  M. Shin,et al.  Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[32]  J. Pouysségur,et al.  Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. , 2000, The Journal of biological chemistry.

[33]  G. Merlino,et al.  Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[35]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[36]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[37]  L. Liotta,et al.  General mechanisms of metastasis , 1997, Cancer.

[38]  H. Lyng,et al.  Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. , 1998, British Journal of Cancer.

[39]  D. Hedley,et al.  Hypoxia-inducible Factor-1 (cid:1) Is an Intrinsic Marker for Hypoxia in Cervical Cancer Xenografts 1 , 2022 .

[40]  K. Miyazawa,et al.  Proteolytic activation of hepatocyte growth factor in response to tissue injury. , 1994, The Journal of biological chemistry.

[41]  L. Trusolino,et al.  Invasive growth: from development to metastasis. , 2002, The Journal of clinical investigation.

[42]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[43]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[44]  P. Accornero,et al.  K252a inhibits the oncogenic properties of Met, the HGF receptor , 2002, Oncogene.

[45]  E. Gherardi,et al.  Regulation of cell movement: the motogenic cytokines. , 1991, Biochimica et biophysica acta.

[46]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[47]  L. Schmidt,et al.  Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. , 1999, Cancer research.

[48]  M. Stella,et al.  Ets up-regulates MET transcription. , 1996, Oncogene.

[49]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[50]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[51]  L. Orci,et al.  Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor , 1991, Cell.

[52]  K. Matsumoto,et al.  HGF: its organotrophic role and therapeutic potential. , 1997, Ciba Foundation symposium.

[53]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[54]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[55]  George M. Hilliard,et al.  Cobalt Inhibits the Interaction between Hypoxia-inducible Factor-α and von Hippel-Lindau Protein by Direct Binding to Hypoxia-inducible Factor-α* , 2003, The Journal of Biological Chemistry.

[56]  K. Tashiro,et al.  Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.

[57]  W. Birchmeier,et al.  Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. , 1997, Ciba Foundation symposium.

[58]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[59]  A. Bardelli,et al.  A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth* , 1999, The Journal of Biological Chemistry.

[60]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[61]  A. Bardelli,et al.  Induction of epithelial tubules by growth factor HGF depends on the STAT pathway , 1998, Nature.

[62]  J. Sleeman,et al.  CD44 is required for two consecutive steps in HGF/c-Met signaling. , 2002, Genes & development.

[63]  S. Giordano,et al.  Structure and inducible regulation of the human MET promoter. , 1994, The Journal of biological chemistry.

[64]  C. Graham,et al.  Oxygen-mediated Regulation of Tumor Cell Invasiveness , 2002, The Journal of Biological Chemistry.

[65]  M. Surani,et al.  Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. , 1996, Developmental genetics.

[66]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[67]  S. Frisch,et al.  Disruption of epithelial cell-matrix interactions induces apoptosis , 1994, The Journal of cell biology.

[68]  W. Birchmeier,et al.  Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland , 1995, The Journal of cell biology.

[69]  M. Pierotti,et al.  Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.

[70]  K. Webster,et al.  Molecular Regulation of the Endothelin-1 Gene by Hypoxia , 2001, The Journal of Biological Chemistry.

[71]  R. Hill,et al.  Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. , 1990, Journal of the National Cancer Institute.

[72]  J. Folkman Angiogenesis research: from laboratory to clinic. , 1999, Forum.

[73]  Giorgio F. Gilestro,et al.  The Semaphorin 4D receptor controls invasive growth by coupling with Met , 2002, Nature Cell Biology.

[74]  Tetsuo Noda,et al.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor , 1995, Nature.

[75]  L. Trusolino,et al.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.

[76]  L. Tacchini,et al.  Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. , 2001, Carcinogenesis.

[77]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[78]  R. Hill,et al.  Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. , 2001, Cancer research.

[79]  L. Trusolino,et al.  A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth , 2001, Cell.

[80]  E Medico,et al.  The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. , 1996, Molecular biology of the cell.

[81]  M. Stella,et al.  Cross-talk between the proto-oncogenes Met and Ron , 2000, Oncogene.

[82]  G. Hannon RNA interference : RNA , 2002 .

[83]  F. Galimi,et al.  Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. , 1994, The Journal of biological chemistry.

[84]  Michael Stoker,et al.  Scatter factor is a fibroblast-derived modulator of epithelial cell mobility , 1987, Nature.

[85]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  J M Brown,et al.  Tumor hypoxia, drug resistance, and metastases. , 1990, Journal of the National Cancer Institute.

[87]  W. Birchmeier,et al.  Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis , 1996, Nature.

[88]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[89]  A. Maity,et al.  Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. , 2000, Experimental cell research.

[90]  P. Vaupel,et al.  Hypoxic cervical cancers with low apoptotic index are highly aggressive. , 1999, Cancer research.

[91]  Q. Xu,et al.  Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium , 2000, The Journal of Biological Chemistry.

[92]  Kunio Matsumoto,et al.  Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor , 1998, Oncogene.

[93]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[94]  M. Lyon,et al.  Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. , 1994, The Journal of biological chemistry.

[95]  M. Makuuchi,et al.  Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. , 2000, Blood.

[96]  E. Medico,et al.  Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum. , 1994, The Journal of biological chemistry.

[97]  H. Augustin,et al.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF‐E, mediates angiogenesis via signalling through VEGFR‐2 (KDR) but not VEGFR‐1 (Flt‐1) receptor tyrosine kinases , 1999, The EMBO journal.